Today, we will present preclinical data supporting the development of ziftomenib for the treatment of advanced gastrointestinal stromal tumors (#GIST) at the EORTC-NCI-AACR Symposium. These new findings highlight the potential of #ziftomenib in combination with KIT inhibitors, including the frontline standard of care imatinib, for the treatment of patients with advanced GIST. Learn more about the data and access the full poster: https://bit.ly/48mvloz #ENASymp24
Kura Oncology, Inc.
Biotechnology Research
San Diego, California 21,688 followers
Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.
About us
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.
- Website
-
http://www.kuraoncology.com
External link for Kura Oncology, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2014
- Specialties
- Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
Locations
-
Primary
12730 High Bluff Dr
Suite 400
San Diego, California 92130, US
-
2 Seaport Ln
Suite 8A
Boston, Massachusetts 02210, US
Employees at Kura Oncology, Inc.
Updates
-
This Friday, we will present preclinical data supporting the combination of our next-generation farnesyl transferase inhibitor (FTI) KO-2806 with targeted therapies, including KRASG12C inhibitors and pan-RAS inhibitors, at the EORTC-NCI-AACR Symposium in Barcelona. Learn more: https://bit.ly/3UgLgio #ENASymp24
-
ACTIVELY RECRUITING patients with R/R NPM1-m #AML co-mutated with FLT3. The KOMET-008 #clinicaltrial is recruiting patients to study #ziftomenib in combination with gilteritinib, a FLT3 inhibitor, for R/R AML. Patients without the FLT3 co-mutation will receive ziftomenib in combination with FLAG-IDA or LDAC. Learn more about enrollment and study locations: https://bit.ly/3B1Ymt7
-
Thank you #TeamKura and The Leukemia & Lymphoma Society for another great annual Light the Night Boston event! The funds raised and awareness generated through this event are crucial to support groundbreaking #bloodcancer research, provide patient care, and advance new treatment options. For our fourth year, we’re proud to participate in this honorable initiative that aims to bring light to the darkness of cancer. Check out the poster and banner decorating booth Kura supported and photos from the event below: #LightTheNight #FightBloodCancer #LightTheNightBoston
-
For the fourth year in a row, #TeamKura was honored to support TeamNEGU: Never Ever Give Up! at their annual #JoyJars event in San Diego and Boston. NEGU’s vision is to become a symbol of help and hope in the childhood cancer space so every child fighting cancer (and their families) have the support and encouragement to #NEGU during their courageous fight. We're proud to join NEGU in their mission to spread joy and encourage every kid fighting cancer to Never Ever Give Up!
-
Could #menin be the key to understanding the development of NPM1-m and KMT2A-r #AML? While menin is known for its multiple functions, it plays a crucial role in regulating gene expression. Emerging research indicates that activation of the menin pathway may significantly impact the development of NPM1-m and KMT2A-r AML, unlocking new insights into the complexities of AML. Kura Oncology is investigating the potential of menin inhibition with #ziftomenib in patients with AML. See ongoing clinical trials: https://bit.ly/3A2vZL1
-
At #FierceJPM Week, CEO Troy Wilson, Ph.D., J.D. gave his insights on the Inflation Reduction Act (#IRA), including how we can move forward in the best interest of patients. Hear more in the clip below and view more highlights from the panel here: https://lnkd.in/g8FgCRCD
-
Congratulations to our very own Chief Operating Officer Kathy Ford for being named in the 2024 PharmaVoice 100 list! This prestigious award recognizes the top 100 influential industry leaders who are devoted to lifting the pillars of #biotech and drug development to new heights. Join us in congratulating Kathy on her accomplishment! See the full list here: https://bit.ly/4gQi6Ah
-
This #HispanicHeritageMonth, we reflect on the remarkable contributions of Hispanic leaders in #biotech and beyond. At Kura, we are proud of the diverse talent that fuels our success. Hear more from #TeamKura member Alma Ortiz on our commitment to inclusivity. #HHM24
-
#TeamKura is proud to join the The Leukemia & Lymphoma Society for our 4th consecutive #LighttheNight event! Together, we're bringing light to the darkness of cancer by supporting groundbreaking research and bringing hope to patients and families battling blood cancers. Join us as we walk to celebrate, honor, and remember those affected. Find a Light the Night walk near you and help shine a light in the fight against blood cancer! https://lnkd.in/dFqbRn8 #LLSUSA